AI assistant
4SC AG — Earnings Release 2010
Mar 22, 2011
5_rns_2011-03-22_57ab9c19-4484-44cc-aa61-d45cdb54d81c.html
Earnings Release
Open in viewerOpens in your device viewer
News Details
Corporate | 22 March 2011 07:30
4SC Full Year Results – Conference Call and Webcast, 29 March, 2011
4SC AG / Key word(s): Final Results
22.03.2011 / 07:30
Planegg-Martinsried, Germany, 22 March, 2011 – 4SC AG (Frankfurt, Prime Standard: VSC) a drug discovery and development company, will announce its results for the financial year 2010 (ended 31 December, 2010) on 29 March, 2011. The senior management team will host a conference call at 3pm CET (9am EST) on the day to inform about the results for the quarter and all important developments in the reporting period.
Access to the presentation slides can be obtained at:
http://4sc290311-live.cyber-presentation.de
Participants can access the conference under the following data:
Date: 29 March, 2011
Time: 3pm CET (9am EST)
Dial-in numbers:
0800 10 12 072 (Germany)
0800-358-0886 (UK)
1-877-941-6012 (USA)
+49 (0) 6103 485 3001 (other countries)
Conference ID: 4421825
Approximately two hours after the live presentation, an audio replay of the conference will be available on the 'investors' section of the homepage www.4sc.com.
For further information please contact:
Yvonne Alexander
4SC AG
Investor & Public Relations
Tel.: +49 (0) 89 70 07 63 – 0
**About 4SC
**
4SC AG (ISIN DE0005753818) is a drug discovery and development company focused on autoimmune and cancer indications. Vidofludimus (4SC-101), a small molecule, is currently in a Phase IIb study in rheumatoid arthritis and has completed a Phase IIa exploratory study in inflammatory bowel disease. The company's lead oncology compound, resminostat (4SC-201), a pan histone deacetylase (HDAC) inhibitor, is in Phase II trials in hepatocellular carcinoma and Hodgkin's lymphoma. Two further oncology compounds, 4SC-203 and 4SC-205 are in Phase I studies. 4SC develops drug candidates until proof-of-concept in order to generate value creating partnerships with the pharmaceutical industry in return for advance and milestone payments as well as royalties.
Founded in 1997, 4SC has 94 employees and has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.
For further information please visit www.4sc.com.
End of Corporate News
22.03.2011 Dissemination of a Corporate News, transmitted by DGAP – a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP’s Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
| Language: | English |
| Company: | 4SC AG |
| Am Klopferspitz 19a | |
| 82152 Martinsried | |
| Deutschland | |
| Phone: | +49 (0)89 7007 63-0 |
| Fax: | +49 (0)89 7007 63-29 |
| E-mail: | [email protected] |
| Internet: | www.4sc.de |
| ISIN: | DE0005753818 |
| WKN: | 575381 |
| Listed: | Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, München, Stuttgart |
| End of News | DGAP News-Service |
| - - - |
| 116287 22.03.2011 |